Targeting non-Hodgkin lymphoma with blinatumomab

References

• Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28(27):4184–4190.
   PubMed Web of Science ®Google Scholar
• Howlader N, Noone AM, Krapcho M et al. SEER Cancer Statistics Review, 1975-2014. Bethesda (MD): National Cancer Institute; [cited 2016 Nov]. SEER data submission, posted to the SEER web site, April 2017. Available from: https://seer.cancer.gov/csr/1975_2014/ .
   Google Scholar
• Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B cell lymphoma: a study by the Group d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–4126.
   PubMed Web of Science ®Google Scholar
• Philip T, Guglielmi C, Hagenbeek A, et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin lymphoma. N Engl J Med. 1995;333:1540–1545.
   PubMed Web of Science ®Google Scholar
• Rummel M, Niederle N, Maschmeyer G, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphoma: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013;381(9873):1203–1210.
   PubMed Web of Science ®Google Scholar
• Loffler A, Kufer P, Lutterbuse R, et al. A recombinant bispecific single-chain antibody, CD19~CD3 induces rapid and high lymphoma-directed cytotoxicity by unstimulated T lymphocytes. Blood. 2000;95(6):2098–2103.
   PubMed Web of Science ®Google Scholar
• Haas C, Krinner E, Brischwein K, et al. Mode of cytotoxic action of T cell-engaging BiTE antibody MT110. Immunobiology. 2009;214(6):441–453.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Bargou R, Ruttinger D, et al. Immunotherapy of lymphoma and leukemia with T cell engaging BiTE antibody blinatumomab. Leuk Lymphoma. 2009;50(6):886–891.
   PubMed Web of Science ®Google Scholar
• Newman MJ, Benani DJ. A review of blinatumomab, a novel immunotherapy. J Oncol Pharm Practice. 2016;22(4):639–645.
   PubMed Web of Science ®Google Scholar
• Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of a T Cell-engaging antibody. Science. 2008;321:974–977.
   PubMed Web of Science ®Google Scholar
• May MB, Glode A. Blinatumomab: A novel, bisepcific, T-cell engaging antibody. Am J Health-Syst Pharm. 2016;73:e6–13.
   PubMed Web of Science ®Google Scholar
• Topp MS, Gokbuget N, Stein AS, et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 2015;16(1):57–66.
   PubMed Web of Science ®Google Scholar
• Goekbuget N, Dombret H, Bonifacio M, et al. BLAST: a confirmatory, single-arm, phase 2 study of blinatumomab, a bispecific T-cell engager (BiTE) antibody construct, in patients with minimal residual disease B-precursor acute lymphoblastic leukemia. Blood. 2014;124(21):379.
   Web of Science ®Google Scholar
• Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017;376(9):836–847.
   PubMed Web of Science ®Google Scholar
• Nagorsen D, Kufer P, Baeuerle PA, et al. Blinatumomab: a historical perspective. Pharmacol Ther. 2012;13693:334–342.
   Web of Science ®Google Scholar
• Goebeler ME, Knop S, Viardot A, et al. Bispecific T-cell engager (BiTE) antibody construct blinatumomab for the treatment of patients with relapsed/refractory non-Hodgkin lymphoma: final results from a phase I study. J Clin Oncol. 2016;34(10):1104–1111.
   PubMed Web of Science ®Google Scholar
• Viardot A, Goebeler ME, Hess G, et al. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma. Blood. 2016;127(11):1410–1416.
   PubMed Web of Science ®Google Scholar
• Amgen. BLINCYTO® (blinatumomab): Full Prescribing Information; 2014. Available from: http://pi.amgen.com/~/media/amgen/repositorysites/pi-amgen-com/blincyto/blincyto_pi_hcp_english.ashx
   Google Scholar
• Pierson R Amgen’s new leukemia drug to carry $178 000 price tag. Reuters [Internet]; 2014 Dec 17 [cited 2016 Feb 6]; HealthNews [page 1]. Available from: http://www.reuters.com/article/us-amgen-cancer-exclusive-idUSKBN0JV1YU20141217
   Google Scholar
• MacDonald D, Prica A, Assouline S, et al. Emerging therapies for the treatment of relapsed or refractory follicular lymphoma. Curr Oncol. 2016;23(6):407–417.
   PubMed Web of Science ®Google Scholar
• Phillips T, Brunvand M, Chen A, et al. Polatuzumab vedotin combined with obinutuzumab for patients with relapsed or refractory non-Hodgkin lymphoma: preliminary safety and clinical activity of a phase Ib/II Study. Blood. 2016;128(22):622.
   Web of Science ®Google Scholar
• Chong EA, Svoboda J, Nasta SD, et al. Chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with poor prognosis, relapsed or refractory CD19+ follicular lymphoma: prolonged remissions relative to antecedent therapy. In: Oral abstract presented at: American Society of Hematology Annual Meeting; 2016 Dec 3-6; San Diego (CA).
   Google Scholar
• Köhnke T, Krupka C, Tischer J, et al. Increase of PD-L1 expressing B-precursor ALL cells in a patient resistant to the CD19/CD3-bispecific T cell engager antibody blinatumomab. J Hematol Oncol. 2015;8:111.
   PubMed Web of Science ®Google Scholar
• Klinger M, Zugmaier G, Naegele V, et al. Pathogenesis-based development of potential mitigation strategies for blinatumomab-associated neurologic events. In: Poster abstract 1589 presented at: American Society of Hematology Annual Meeting; 2016 Dec 3-6; San Diego (CA).
   Google Scholar
• Goebeler M, Viardot A, Noppeney R, et al. CD3/CD19 bispecific BiTE antibody blinatumomab treatment of non-Hodgkin lymphoma (NHL) patients: 60 μg/m2/d by continuous infusion is tolerable and results in durable responses [abstract 0559]. Haematologica. 2010;95(Suppl.2):230.
   Google Scholar
• Feucht J, Kayser S, Gorodezki D, et al. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts. Oncotarget. 2016;7(47):76902–76919.
   PubMed Web of Science ®Google Scholar
• Ueda M, De Lima M, Caimi P, et al. Concurrent blinatumomab and donor lymphocyte infusions for treatment of relapsed pre-B-cell ALL after allogeneic hematopoietic cell transplant. Bone Marrow Transplant. 2016;51(9):1253–1255.
   PubMed Web of Science ®Google Scholar